EC
AEON icon

Elequin Capital’s AEON Biopharma AEON Stock Holding History

Elequin Capital’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-808
Closed -$585K – 313
2022
Q4 		$585K Buy
808
+798
+7,980% +$572K 0.16% 88
2022
Q3 		$7K Buy
+10
New +$7.08K ﹤0.01% 295

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Elequin Capital's AEON Position: Q1 2023 in Review

Elequin Capital sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 808 shares — an estimated $585K sold.

Elequin Capital first reported a position in AEON in Q3 2022 and held it in 2 quarters. The position peaked at $585K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Elequin Capital reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Elequin Capital sold 808 AEON Biopharma shares in Q1 2023, an estimated $585K.
  • Elequin Capital first reported a position in AEON Biopharma in Q3 2022 and held it in 2 quarters.
  • Elequin Capital's AEON Biopharma position peaked at $585K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Elequin Capital's 13F filing for Q1 2023, filed 11 May 2023.